Candel shares are moving lower on Friday after the company priced its $80 million underwritten public offering of shares and ...

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company. Gloperba® is the subject of an exclusive, transferable license to use the ...

Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological ...

Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological ...

(RTTNews) - Candel Therapeutics, Inc. (CADL) announced the pricing of an underwritten public offering of 10,000,001 shares at $6 per share and pre-funded warrants to purchase up to an aggregate of ...

Candel Therapeutics (CADL) announced the launch of an underwritten public offering of $80M of its common stock and, in lieu of common stock to ...

Candel Therapeutics (NASDAQ:CADL) priced an underwritten public offering of 10M shares at $6.00 per share and pre-funded ...

All of the shares and pre-funded warrants in the offering are to be sold by Revolution Medicines. In addition, Revolution Medicines has granted the underwriters a 30-day option to purchase up to an ...

QXO disrupts building products distribution with $4 billion raised for acquisitions & tech, offering special investment ...

In a significant development, Lichen China Limited recently announced a definitive agreement with several investors for the purchase and sale of 15,000,000 of its Class A ordinary shares. These shares ...

NEW YORK – Candel Therapeutics on Thursday priced a public offering of common stock and pre-funded warrants that is expected to bring in $80 million in gross proceeds. The Needham, Massachusetts-based ...

US stock futures were rising in Friday's premarket session as investors looked to end the week on a positive note. Dow Jones Industrial Average futures were up 0.14%, S&P 500 futures gained 0.35%, and ...